170 related articles for article (PubMed ID: 2973122)
1. Endocrinological effects of treatment with high doses of medroxyprogesterone acetate in patients with renal or prostatic adenocarcinoma.
Tomic R; Ljungberg B; Damber JE
Scand J Urol Nephrol Suppl; 1988; 110():185-7. PubMed ID: 2973122
[No Abstract] [Full Text] [Related]
2. High-dose medroxyprogesterone acetate in patients with renal adenocarcinoma and measurable lung metastases: a phase II study.
Kjaer M; Frederiksen PL
Cancer Treat Rep; 1986 Mar; 70(3):431-2. PubMed ID: 2937534
[No Abstract] [Full Text] [Related]
3. Hormonal effects of high dose medroxyprogesterone acetate treatment in males with renal or prostatic adenocarcinoma.
Tomić R; Ljungberg B; Damber JE
Scand J Urol Nephrol; 1988; 22(1):15-8. PubMed ID: 2968646
[TBL] [Abstract][Full Text] [Related]
4. Effects of high dose medroxyprogesterone acetate treatment on antithrombin III and other plasma proteins in males with renal cell or prostatic carcinoma.
Nilsson TK; Tomic R; Ljungberg B
Scand J Urol Nephrol; 1989; 23(1):11-4. PubMed ID: 2522237
[TBL] [Abstract][Full Text] [Related]
5. [Pain relief by high-dose medroxyprogesterone acetate in advanced prostatic cancer].
Sasagawa I; Satomi S; Umeda K; Katayama T
Hinyokika Kiyo; 1989 Apr; 35(4):603-8. PubMed ID: 2525316
[TBL] [Abstract][Full Text] [Related]
6. An overview of clinical trials with high-dose medroxyprogesterone acetate (HD-MPA) in endocrine-related tumors other than breast cancer.
Robustelli della Cuna G; Zanon P; Pavesi L; Preti P; Prada GA; Decensi A
Chemioterapia; 1986 Jun; 5(3):164-72. PubMed ID: 2941173
[TBL] [Abstract][Full Text] [Related]
7. [High-dosage medroxyprogesterone acetate treatment in advanced prostatic cancer].
Flamm J; Spona J
Wien Klin Wochenschr; 1987 Oct; 99(19):682-6. PubMed ID: 2961131
[TBL] [Abstract][Full Text] [Related]
8. Re: Deoxyribonucleic acid content and medroxyprogesterone acetate treatment in metastatic renal cell carcinoma.
Neuwirth H; Blyth B; Richie AW; Taube DM; deKernion JB
J Urol; 1990 Sep; 144(3):749-50. PubMed ID: 2143789
[No Abstract] [Full Text] [Related]
9. The role of medroxyprogesterone acetate (MPA) in the treatment of renal adenocarcinoma.
Kjaer M
Cancer Treat Rev; 1988 Sep; 15(3):195-209. PubMed ID: 2974757
[No Abstract] [Full Text] [Related]
10. Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma.
Lee CP; Patel PM; Selby PJ; Hancock BW; Mak I; Pyle L; James MG; Beirne DA; Steeds S; A'Hern R; Gore ME; Eisen T
J Clin Oncol; 2006 Feb; 24(6):898-903. PubMed ID: 16484699
[TBL] [Abstract][Full Text] [Related]
11. [the oral use of a progestational hormone (Provera 100) as an adjuvant in therapy of adenocarcinoma of the kidney. Preliminary report].
Liberti M; Di Silverio F; Concolino G; Tenaglia R; Marocchi A
Minerva Urol; 1980; 32(3):175-8. PubMed ID: 7432332
[TBL] [Abstract][Full Text] [Related]
12. [Experiences with Depo-Provera (medroxyprogesterone) in the treatment of kidney tumors].
Balogh F; Romics I
Z Urol Nephrol; 1987 Aug; 80(8):449-53. PubMed ID: 2961162
[TBL] [Abstract][Full Text] [Related]
13. EORTC protocol 30761: a randomized study of non-metastatic and metastatic prostatic cancer treated by cyproterone acetate versus diethylstilbestrol and medroxyprogesterone acetate. European Organization for Research on Treatment of Cancer Urological Group.
Pavone-Macaluso M; Schröder FH; de Voogt HJ; Viggiano G; Barasolo E; Lardennois B; de Pauw M; Sylvester R; Smith PH; Suciu S
Prog Clin Biol Res; 1989; 303():111-6. PubMed ID: 2528735
[No Abstract] [Full Text] [Related]
14. Advanced adenocarcinoma of the kidney: therapy with lomustine, vinblastine, hydroxyurea, and medroxyprogesterone acetate and regression analysis of factors relating to survival.
Brubaker LH; Troner MB; Birch R
Cancer Treat Rep; 1983; 67(7-8):741-2. PubMed ID: 6223695
[No Abstract] [Full Text] [Related]
15. Treatment of rat prostatic adenocarcinoma with medroxyprogesterone acetate (MPA): effects on growth and morphology.
Damber JE; Bergh A; Landström M; Tomić R
J Urol; 1991 Jun; 145(6):1283-7. PubMed ID: 1827847
[TBL] [Abstract][Full Text] [Related]
16. Chemo-hormonal therapy for metastatic renal cell carcinoma with adriamycin, hydroxyurea, vinblastine, and medroxyprogesterone acetate.
Katakkar SB; Franks CR
Cancer Treat Rep; 1978 Sep; 62(9):1379-80. PubMed ID: 688282
[TBL] [Abstract][Full Text] [Related]
17. Effect of medroxyprogesterone acetate and doxorubicin on sublines of 13762 mammary adenocarcinoma in rats.
Formelli F; Zaccheo T; Casazza AM; Bellini O; Di Marco A
Eur J Cancer Clin Oncol; 1981 Nov; 17(11):1211-21. PubMed ID: 6460631
[No Abstract] [Full Text] [Related]
18. Lessons from phase III-trials on the hormonal treatment of prostatic cancer. I: Results of EORTC-trials 30761 and 30762.
de Voogt HJ; Pavone-Macaluso M; Smith PH; de Pauw M; Suciu S
Prog Clin Biol Res; 1988; 260():111-7. PubMed ID: 2966403
[No Abstract] [Full Text] [Related]
19. [Clinovir treatment of adenocarcinoma of the uterus with lung metastases].
Stertmann WA; Hocke M; Röttger P
MMW Munch Med Wochenschr; 1983 Jul; 125(29-30):685-6. PubMed ID: 6225946
[No Abstract] [Full Text] [Related]
20. [The treatment of metastasizing hypernephroid (renal cell) carcinoma with medroxyprogesterone acetate (Clinovir) (author's transl].
von Lieven H; Hahn D
MMW Munch Med Wochenschr; 1977 Aug; 119(34):1089-92. PubMed ID: 408657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
